Symbol not found

0.00 (0.00%)
Products, Expansion, Regulatory

Immunomedics Says Trodelvy extends survival in breast cancer patients

Published: 09/19/2020 14:41 GMT
(IMMU) - Immunomedics Says Trodelvy Significantly Extends Survival in Phase 3 Ascent Study of Metastatic Triple-negative Breast Cancer (mtnbc).
Immunomedics Says Trodelvy Significantly Reduced the Risk of Death by 52%, With a Median Overall Survival of 12.1 Months.
Immunomedics - Plan to Submit a Marketing Authorization Application to European Medicines Agency in H1 2021 for Trodelvy.
Immunomedics - Phase 3 Ascent Study Showed Trodelvy Improved Overall Response Rate & Clinical Benefit Rate Versus Standard Single-agent Chemotherapy.
Immunomedics - Trodelvy Was Well Tolerated by Patients in the Ascent Study and No New Safety Signals Were Observed.
Immunomedics Says Sbla for Full Approval to Be Submitted in Q4 Under Rtor Process for Trodelvy in Mtnbc.